Plain-English translation of NCT05583071 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of four medications—, , (Minjuvi®), and (Revlimid®)—to treat people with primary central nervous system lymphoma (PCNSL), a cancer that starts in the brain. The study is for patients who have never been treated before and are not candidates for stem cell transplant. Researchers want to see how well this medication combination works and how safe it is.
PCNSL is a rare type of brain cancer, and treatment options are limited, especially for older patients or those too sick for stem cell transplant. This trial is testing whether this new combination of medications can help patients who have few other options.
You likely qualify if…
You likely don't qualify if…
You will receive treatment over 84 days (about 3 months), given in four 21-day cycles. Each cycle includes intravenous infusions of the medications on specific days and oral pills you take at home. The trial involves regular visits to the hospital or clinic for infusions and blood tests. You will be followed closely for one year total to monitor how well the treatment works and watch for side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany